← Back to Search

Device Validation Using Blood Samples for Thrombotic Thrombocytopenic Purpura

N/A
Recruiting
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial is for a new device that needs to be validated with known samples. 3 ml of blood is needed from people diagnosed with hTTP. You will be compensated for your time and resources.

Who is the study for?
This trial is for individuals with hereditary thrombotic thrombocytopenic purpura (hTTP) who have an ADAMTS13 activity level below 1%. Participants will provide a small blood sample and receive $500 for their time.
What is being tested?
The study involves a single blood draw to help validate a new diagnostic device. The company behind this has other devices on the market, and needs real patient samples to ensure the new instrument works correctly.
What are the potential side effects?
Since the intervention only includes drawing blood, side effects are minimal but may include slight pain or bruising at the needle site, dizziness, or fainting.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

1Treatment groups
Placebo Group
Group I: ParticipantsPlacebo Group1 Intervention
Anyone with Hereditary TTP

Find a Location

Who is running the clinical trial?

Media Library

Blood Draw Clinical Trial Eligibility Overview. Trial Name: IL — N/A
Thrombotic Thrombocytopenic Purpura Research Study Groups: Participants
Thrombotic Thrombocytopenic Purpura Clinical Trial 2023: Blood Draw Highlights & Side Effects. Trial Name: IL — N/A
Blood Draw 2023 Treatment Timeline for Medical Study. Trial Name: IL — N/A
~100 spots leftby Dec 2025